Durvalumab and BCG (induction and maintenance)
You have durvalumab as a
drip into a vein (intravenously) every 4 weeks, for a year.
You also have BCG as a treatment into your bladder (intravesical). You have it:
- once a week for 6 weeks
- then once a week for 3 weeks at set months during this trial. Your doctor will give you more information about how often you have it
Durvalumab and BCG (induction only)
You have durvalumab as a drip into your vein every 4 weeks, for a year. And BCG as a treatment into your bladder once a week, for 6 weeks.
BCG (induction and maintenance)
You have BCG as a treatment into your bladder. You have it:
- once a week for 6 weeks
- then once a week for 3 weeks at set months during this trial. Your doctor will give you more information about how often you have this
Tissue sample
The trial team ask to use a tissue sample of your cancer taken when you had an operation or a biopsy. You need to have a new sample taken if there isn’t a suitable sample available.
The trial doctors may also ask you to have a new sample taken if your cancer comes back.
Blood tests
You have extra blood tests as part of this trial. You have them before the start of treatment and then:
- at set times during this trial
- at 4 weeks, 8 weeks and 12 weeks after you finish treatment
Researchers want to look for biomarkers and find out what happens to durvalumab in your body.
Quality of life questionnaire
This continues for as long as you are having treatment or tests that are part of this trial.